← Leaderboards
Thor Andrew Wagner
Seattle Children'S Hospital
$2,566,332
Attributed
$2,566,332
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $489K · FY2008–18$500K$375K$250K$125K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$2,566,332 · 2
By mechanism
R01$1,919,007 · 1
K23$647,325 · 1
Top collaborators
No co-investigators on record.
Most similar at Seattle Children'S Hospital
Same institution · by research overlap
- Nicole H Tobin$172,962
- Angela Jean Peck Campbell$681,922
Others in their field
Top investigators on “Peripheral Blood Mononuclear Cell”
- Lawrence Corey · Fred Hutchinson Cancer Center$212,604,669
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$105,253,810
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$82,236,778
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$75,163,168
- Joseph B. Margolick · Johns Hopkins University$74,328,642
- Constance Ann Benson · University Of California, San Diego$65,790,143
Research focus
Peripheral Blood Mononuclear CellCellsAffectBaseAntiretroviral TherapyInsightLymphocytePlasmaViralVirusAnti-Retroviral AgentsPharmacologyAntigensConsultationsCareerAcuteCommunitiesDetectionChildCohortCharacteristicsChildhoodBloodCollaborations
Grant awards (9)
Engineering T-cells with optimized anti-HIV chimeric antigen receptors and CCR5 disruption as a strategy to target HIV-infected cells$465,552
R01 · FY2018 · AI · contact PI
Engineering T-cells with optimized anti-HIV chimeric antigen receptors and CCR5 disruption as a strategy to target HIV-infected cells$488,955
R01 · FY2017 · AI · contact PI
Engineering T-cells with optimized anti-HIV chimeric antigen receptors and CCR5 disruption as a strategy to target HIV-infected cells$482,250
R01 · FY2016 · AI · contact PI
Engineering T-cells with optimized anti-HIV chimeric antigen receptors and CCR5 disruption as a strategy to target HIV-infected cells$482,250
R01 · FY2015 · AI · contact PI
Persistent HIV-1 Replication in the Respiratory Tract Despite ART$129,465
K23 · FY2012 · AI · contact PI
Persistent HIV-1 Replication in the Respiratory Tract Despite ART$129,465
K23 · FY2011 · AI · contact PI
Persistent HIV-1 Replication in the Respiratory Tract Despite ART$129,465
K23 · FY2010 · AI · contact PI
Persistent HIV-1 Replication in the Respiratory Tract Despite ART$129,465
K23 · FY2009 · AI · contact PI
Persistent HIV-1 Replication in the Respiratory Tract Despite ART$129,465
K23 · FY2008 · AI · contact PI